tiprankstipranks
Revive Therapeutics Advances Psilocybin Study
PremiumCompany AnnouncementsRevive Therapeutics Advances Psilocybin Study
1M ago
Revive provides update on psilocybin study for methamphetamine use disorder
PremiumThe Fly
Revive provides update on psilocybin study for methamphetamine use disorder
1M ago
Revive Therapeutics Provides Update on Psilocybin Clinical Study for Methamphetamine Use Disorder
PremiumPress Releases
Revive Therapeutics Provides Update on Psilocybin Clinical Study for Methamphetamine Use Disorder
1M ago
Revive Therapeutics To Submit Type C Meeting Request with FDA for Bucillamine to Treat Long COVID
PremiumPress ReleasesRevive Therapeutics To Submit Type C Meeting Request with FDA for Bucillamine to Treat Long COVID
2M ago
Revive Therapeutics to submit Type C meeting request with FDA for bucillamine
PremiumThe Fly
Revive Therapeutics to submit Type C meeting request with FDA for bucillamine
2M ago
Revive Therapeutics offers update on research, clinical, regulatory initiatives
PremiumThe Fly
Revive Therapeutics offers update on research, clinical, regulatory initiatives
2M ago
Revive Therapeutics explores use of bucillamine for long COVID
PremiumThe FlyRevive Therapeutics explores use of bucillamine for long COVID
3M ago
Revive Therapeutics Explores the Use of Bucillamine for Long COVID
PremiumPress Releases
Revive Therapeutics Explores the Use of Bucillamine for Long COVID
3M ago
Revive Therapeutics Ltd. Announces Closing of the First Tranche of Its Private Placement for Gross Proceeds of $913,500
PremiumPress Releases
Revive Therapeutics Ltd. Announces Closing of the First Tranche of Its Private Placement for Gross Proceeds of $913,500
3M ago

Trending

Name
Price
Price Change
S&P 500
Dow Jones
Nasdaq 100